Abstract
Summary
LPI (LP Information)' newest research report, the “Axitinib API Industry Forecast” looks at past sales and reviews total world Axitinib API sales in 2022, providing a comprehensive analysis by region and market sector of projected Axitinib API sales for 2023 through 2029. With Axitinib API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Axitinib API industry.
This Insight Report provides a comprehensive analysis of the global Axitinib API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Axitinib API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Axitinib API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Axitinib API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Axitinib API.
The global Axitinib API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Axitinib API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Axitinib API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Axitinib API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Axitinib API players cover Hunan Huateng Pharmaceutical, Zhejiang Jiuzhou Pharmaceutical, Beijing Mesochem Technology, Guangdong Raffles PharmaTech, Hangzhou Longshine Bio-Tech, Shenzhen HwaGen Pharmaceutical, Alembic Pharmaceuticals, Anax Laboratories and Biotechnica Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Axitinib API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
0.95
0.98
0.99
Others
Segmentation by application
Injection
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Hunan Huateng Pharmaceutical
Zhejiang Jiuzhou Pharmaceutical
Beijing Mesochem Technology
Guangdong Raffles PharmaTech
Hangzhou Longshine Bio-Tech
Shenzhen HwaGen Pharmaceutical
Alembic Pharmaceuticals
Anax Laboratories
Biotechnica Pharma
DEAFARMA
Hetero Drugs
MSN Laboratories
Shilpa Medicare
Key Questions Addressed in this Report
What is the 10-year outlook for the global Axitinib API market?
What factors are driving Axitinib API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Axitinib API market opportunities vary by end market size?
How does Axitinib API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
This Insight Report provides a comprehensive analysis of the global Axitinib API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Axitinib API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Axitinib API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Axitinib API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Axitinib API.
The global Axitinib API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Axitinib API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Axitinib API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Axitinib API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Axitinib API players cover Hunan Huateng Pharmaceutical, Zhejiang Jiuzhou Pharmaceutical, Beijing Mesochem Technology, Guangdong Raffles PharmaTech, Hangzhou Longshine Bio-Tech, Shenzhen HwaGen Pharmaceutical, Alembic Pharmaceuticals, Anax Laboratories and Biotechnica Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Axitinib API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
0.95
0.98
0.99
Others
Segmentation by application
Injection
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Hunan Huateng Pharmaceutical
Zhejiang Jiuzhou Pharmaceutical
Beijing Mesochem Technology
Guangdong Raffles PharmaTech
Hangzhou Longshine Bio-Tech
Shenzhen HwaGen Pharmaceutical
Alembic Pharmaceuticals
Anax Laboratories
Biotechnica Pharma
DEAFARMA
Hetero Drugs
MSN Laboratories
Shilpa Medicare
Key Questions Addressed in this Report
What is the 10-year outlook for the global Axitinib API market?
What factors are driving Axitinib API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Axitinib API market opportunities vary by end market size?
How does Axitinib API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Axitinib API Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Axitinib API by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Axitinib API by Country/Region, 2018, 2022 & 2029
2.2 Axitinib API Segment by Type
2.2.1 0.95
2.2.2 0.98
2.2.3 0.99
2.2.4 Others
2.3 Axitinib API Sales by Type
2.3.1 Global Axitinib API Sales Market Share by Type (2018-2023)
2.3.2 Global Axitinib API Revenue and Market Share by Type (2018-2023)
2.3.3 Global Axitinib API Sale Price by Type (2018-2023)
2.4 Axitinib API Segment by Application
2.4.1 Injection
2.4.2 Others
2.5 Axitinib API Sales by Application
2.5.1 Global Axitinib API Sale Market Share by Application (2018-2023)
2.5.2 Global Axitinib API Revenue and Market Share by Application (2018-2023)
2.5.3 Global Axitinib API Sale Price by Application (2018-2023)
3 Global Axitinib API by Company
3.1 Global Axitinib API Breakdown Data by Company
3.1.1 Global Axitinib API Annual Sales by Company (2018-2023)
3.1.2 Global Axitinib API Sales Market Share by Company (2018-2023)
3.2 Global Axitinib API Annual Revenue by Company (2018-2023)
3.2.1 Global Axitinib API Revenue by Company (2018-2023)
3.2.2 Global Axitinib API Revenue Market Share by Company (2018-2023)
3.3 Global Axitinib API Sale Price by Company
3.4 Key Manufacturers Axitinib API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Axitinib API Product Location Distribution
3.4.2 Players Axitinib API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Axitinib API by Geographic Region
4.1 World Historic Axitinib API Market Size by Geographic Region (2018-2023)
4.1.1 Global Axitinib API Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Axitinib API Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Axitinib API Market Size by Country/Region (2018-2023)
4.2.1 Global Axitinib API Annual Sales by Country/Region (2018-2023)
4.2.2 Global Axitinib API Annual Revenue by Country/Region (2018-2023)
4.3 Americas Axitinib API Sales Growth
4.4 APAC Axitinib API Sales Growth
4.5 Europe Axitinib API Sales Growth
4.6 Middle East & Africa Axitinib API Sales Growth
5 Americas
5.1 Americas Axitinib API Sales by Country
5.1.1 Americas Axitinib API Sales by Country (2018-2023)
5.1.2 Americas Axitinib API Revenue by Country (2018-2023)
5.2 Americas Axitinib API Sales by Type
5.3 Americas Axitinib API Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Axitinib API Sales by Region
6.1.1 APAC Axitinib API Sales by Region (2018-2023)
6.1.2 APAC Axitinib API Revenue by Region (2018-2023)
6.2 APAC Axitinib API Sales by Type
6.3 APAC Axitinib API Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Axitinib API by Country
7.1.1 Europe Axitinib API Sales by Country (2018-2023)
7.1.2 Europe Axitinib API Revenue by Country (2018-2023)
7.2 Europe Axitinib API Sales by Type
7.3 Europe Axitinib API Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Axitinib API by Country
8.1.1 Middle East & Africa Axitinib API Sales by Country (2018-2023)
8.1.2 Middle East & Africa Axitinib API Revenue by Country (2018-2023)
8.2 Middle East & Africa Axitinib API Sales by Type
8.3 Middle East & Africa Axitinib API Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Axitinib API
10.3 Manufacturing Process Analysis of Axitinib API
10.4 Industry Chain Structure of Axitinib API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Axitinib API Distributors
11.3 Axitinib API Customer
12 World Forecast Review for Axitinib API by Geographic Region
12.1 Global Axitinib API Market Size Forecast by Region
12.1.1 Global Axitinib API Forecast by Region (2024-2029)
12.1.2 Global Axitinib API Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Axitinib API Forecast by Type
12.7 Global Axitinib API Forecast by Application
13 Key Players Analysis
13.1 Hunan Huateng Pharmaceutical
13.1.1 Hunan Huateng Pharmaceutical Company Information
13.1.2 Hunan Huateng Pharmaceutical Axitinib API Product Portfolios and Specifications
13.1.3 Hunan Huateng Pharmaceutical Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Hunan Huateng Pharmaceutical Main Business Overview
13.1.5 Hunan Huateng Pharmaceutical Latest Developments
13.2 Zhejiang Jiuzhou Pharmaceutical
13.2.1 Zhejiang Jiuzhou Pharmaceutical Company Information
13.2.2 Zhejiang Jiuzhou Pharmaceutical Axitinib API Product Portfolios and Specifications
13.2.3 Zhejiang Jiuzhou Pharmaceutical Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Zhejiang Jiuzhou Pharmaceutical Main Business Overview
13.2.5 Zhejiang Jiuzhou Pharmaceutical Latest Developments
13.3 Beijing Mesochem Technology
13.3.1 Beijing Mesochem Technology Company Information
13.3.2 Beijing Mesochem Technology Axitinib API Product Portfolios and Specifications
13.3.3 Beijing Mesochem Technology Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Beijing Mesochem Technology Main Business Overview
13.3.5 Beijing Mesochem Technology Latest Developments
13.4 Guangdong Raffles PharmaTech
13.4.1 Guangdong Raffles PharmaTech Company Information
13.4.2 Guangdong Raffles PharmaTech Axitinib API Product Portfolios and Specifications
13.4.3 Guangdong Raffles PharmaTech Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Guangdong Raffles PharmaTech Main Business Overview
13.4.5 Guangdong Raffles PharmaTech Latest Developments
13.5 Hangzhou Longshine Bio-Tech
13.5.1 Hangzhou Longshine Bio-Tech Company Information
13.5.2 Hangzhou Longshine Bio-Tech Axitinib API Product Portfolios and Specifications
13.5.3 Hangzhou Longshine Bio-Tech Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Hangzhou Longshine Bio-Tech Main Business Overview
13.5.5 Hangzhou Longshine Bio-Tech Latest Developments
13.6 Shenzhen HwaGen Pharmaceutical
13.6.1 Shenzhen HwaGen Pharmaceutical Company Information
13.6.2 Shenzhen HwaGen Pharmaceutical Axitinib API Product Portfolios and Specifications
13.6.3 Shenzhen HwaGen Pharmaceutical Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Shenzhen HwaGen Pharmaceutical Main Business Overview
13.6.5 Shenzhen HwaGen Pharmaceutical Latest Developments
13.7 Alembic Pharmaceuticals
13.7.1 Alembic Pharmaceuticals Company Information
13.7.2 Alembic Pharmaceuticals Axitinib API Product Portfolios and Specifications
13.7.3 Alembic Pharmaceuticals Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Alembic Pharmaceuticals Main Business Overview
13.7.5 Alembic Pharmaceuticals Latest Developments
13.8 Anax Laboratories
13.8.1 Anax Laboratories Company Information
13.8.2 Anax Laboratories Axitinib API Product Portfolios and Specifications
13.8.3 Anax Laboratories Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Anax Laboratories Main Business Overview
13.8.5 Anax Laboratories Latest Developments
13.9 Biotechnica Pharma
13.9.1 Biotechnica Pharma Company Information
13.9.2 Biotechnica Pharma Axitinib API Product Portfolios and Specifications
13.9.3 Biotechnica Pharma Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Biotechnica Pharma Main Business Overview
13.9.5 Biotechnica Pharma Latest Developments
13.10 DEAFARMA
13.10.1 DEAFARMA Company Information
13.10.2 DEAFARMA Axitinib API Product Portfolios and Specifications
13.10.3 DEAFARMA Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 DEAFARMA Main Business Overview
13.10.5 DEAFARMA Latest Developments
13.11 Hetero Drugs
13.11.1 Hetero Drugs Company Information
13.11.2 Hetero Drugs Axitinib API Product Portfolios and Specifications
13.11.3 Hetero Drugs Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Hetero Drugs Main Business Overview
13.11.5 Hetero Drugs Latest Developments
13.12 MSN Laboratories
13.12.1 MSN Laboratories Company Information
13.12.2 MSN Laboratories Axitinib API Product Portfolios and Specifications
13.12.3 MSN Laboratories Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 MSN Laboratories Main Business Overview
13.12.5 MSN Laboratories Latest Developments
13.13 Shilpa Medicare
13.13.1 Shilpa Medicare Company Information
13.13.2 Shilpa Medicare Axitinib API Product Portfolios and Specifications
13.13.3 Shilpa Medicare Axitinib API Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Shilpa Medicare Main Business Overview
13.13.5 Shilpa Medicare Latest Developments
14 Research Findings and Conclusion